BerGenBio

BerGenBio ASA is a Norwegian clinical-stage biopharmaceutical company focused on oncology. Based in Bergen, it develops selective inhibitors of AXL, a receptor tyrosine kinase associated with tumor growth, metastasis, and resistance to therapy. AXL signaling is also implicated in immune evasion, making AXL inhibitors a potential approach to enhance cancer therapies.

The lead candidate bemcentinib (BGB324) is an oral AXL inhibitor designed to block AXL signaling, potentially slowing tumor progression and enhancing anti-tumor immune responses. Bemcentinib has been evaluated in multiple clinical trials across various cancer indications, both as a single agent and in combination with other therapies, including immune checkpoint inhibitors.

In addition to bemcentinib, BerGenBio pursues other research programs targeting AXL and related pathways; several programs are in preclinical or early clinical development. The company collaborates with partners to advance its portfolio and to expand its biomarkers and diagnostic tools, aiming to identify patients most likely to benefit from AXL-targeted therapies.

BerGenBio is publicly traded on the Oslo Stock Exchange, with its development trajectory tied to clinical trial outcomes and regulatory approvals for bemcentinib and future assets. The company maintains a focused strategy on translating AXL biology into oncology therapeutics through a combination of clinical development and external collaborations.